We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Inexpensive Test Rapidly Identifies Resistant Infections

By LabMedica International staff writers
Posted on 24 Sep 2014
The protocol for a relatively new test for a dangerous form of Gram-negative bacteria antibiotic resistance has been modified increasing its specificity to 100%.

Polymerase chain reaction (PCR), a DNA-based test, is currently the gold standard for detecting carbapenem-resistant Enterobacteriaceae (CRE), but it is expensive and requires equipment that many laboratories do not have, especially in low-income countries that are large reservoirs for CRE. More...


Microbiologists at the Oregon State Public Health Laboratory (Portland, OR, USA) used a modification of the test, called Carba NP, which was originally developed at the University of Fribourg (Switzerland) and the University Hospital of the South-Paris Medical School (France), to rapidly identify CRE, often referred to in the media as "super bugs" for their ability to resist most major antibiotics.

The scientists evaluated the ability of the Carba NP test to properly identify 59 of the 201 clinical isolates as carbapenemase producers. They used a previously published protocol and correctly identified 92% as being carbapenemase producers, including all strains of New Delhi metallo-beta-lactamase-1 (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC), two important types of CRE. When they adjusted the protocol to increase the inoculum size and tested again they achieved 100% sensitivity. The average time to complete a test was 2.5 hours.

Karim Morey-Castro, PSM, a coauthor of the study, said, “Over the past decade carbapenemase-producing CRE (CP-CRE) have rapidly spread around the globe and are currently considered an urgent public health threat by the [US] Centers for Disease Control and Prevention (CDC). Timely detection of CP-CRE is critical to patient care and infection control. Carba NP is a much less expensive test that most labs should be able to afford.” The study was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy held September 5–9, 2014, in Washington DC (USA).

Related Links:

Oregon State Public Health Laboratory
University of Fribourg
University Hospital of the South-Paris Medical School



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.